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ABSTRACT OF THESIS

Nutritional Status in Critical Care of COVID-19 Patients

Critical care nutrition is a poorly researched, and such a sudden pandemic event
requiring manipulation of nutritional status via propofol-induced sedation for mechanical
ventilation is potentially impactful on patient outcomes. This paper seeks to provide
context to the impact of critical care protocols on the nutritional status of obese patients
suffering from COVID-19.
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Chapter One: Introduction
Background
Overview of COVID-19
Reported in December 2019 in the Wuhan province of China as a pneumonia of
unknown etiology, the severe acute respiratory syndrome coronavirus-2, SARS-CoV-2,
causing the respiratory disease, COVID-19, has resulted in the greatest public health
emergency of the 21st century to date. Globally speaking, males have worse COVID-19
outcomes than females. For instance, as of writing, male patients make up roughly equal
numbers of cases compared to female patients, but are make up 55% of hospitalizations,
63% of ICU admissions, and 57% of deaths worldwide at the end of 20211. Discussion of
possible causes for the discrepancy between sexes will be discussed in later sections, but
there is a clear marked difference in outcomes on sex-determined lines even in wealthier
cohorts with greater resources.
Obesity greatly increases risk for adverse outcomes related to COVID-19. Nearly
two-thirds of the adult population in the United States is obese. There are sex differences
in the prevalence of obesity, with more women having obesity compared to men. Further,
susceptibility to SARS-CoV-2 infection and risk for adverse outcomes of COVID-19 is
increased by the presence of obesity-related co-morbidities, such as hypertension, of which
sex differences also exist. It is not known how the confluence of sex and obesity contribute
to greater disease severity in men.
Patients with COVID-19 admitted to critical care, usually with acute respiratory failure,
are usually subjected to long periods of mechanical ventilation and receive supplemental
nutrition. Critical care nutrition is an important mediator of outcomes. The presence of
1

obesity presents many challenges to nutrition in a critical care setting. One such challenge
is the administration of propofol, an intravenously-administered anesthetic that is delivered
in a highly lipophilic emulsion. Effects of increased use of this agent with prolonged
mechanical ventilation in patients COVID-19 on critical care nutrition is not wellunderstood.

1.2 Problem: Whether sex differences in critical nutrition care contributes to adverse
outcomes in COVID-19 is not known.

1.3 Hypothesis: We hypothesize that sex differences in critical care nutrition may
contribute lower energy intake and poor outcomes in patients with COVID-19 in the ICU
at the University of Kentucky.

1.4 Research questions:
1. Do sex differences in prevalence of SARS-CoV-2 diagnosis and COVID-19 ICU
admission at UK follow global trends?
2. Is there a difference in energy intake in men versus women in critical care with
COVID-19, and is this affected by propofol delivery?

1.5 Impact
The rationale for these studies is that improved information about critical care nutrition
management in COVID-19, including sex-based differences, could lead to improved
outcomes.

2

Chapter Two: Literature Review
2.1 COVID-19 and Obesity
Overweight and obesity are
defined as abnormal or
excessive fat accumulation
(respectively) that present a
risk to health. It is usually
Table 1 Classification of Obesity Using Body-Mass Index

categorized using Body Mass
Index (BMI) calculated from

weight divided by height and waist circumference to measure abdominal adiposity, or via
Dual Energy X-ray Absorptiometry (DEXA) to analyze body composition. BMI
Categorization of individuals broadly falls into 6 major categories indicated in Table 12.
As of 1962, approximately 45% of American adults were overweight or obese. By 2018,
The prevalence of overweight or obesity in the United States had increased to
73.6%.Obesity is a strong risk factor for risk of hospitalization and needing critical care
treatment in persons infected with SARS-CoV-2. The global prevalence of obesity is
high, and a recent study demonstrates that even controlled for age, gender, and
comorbidities, obesity is independently associated with increased fatality and major
adverse cardiac and cerebrovascular events in hospitalized patients with COVID-19 3.
Obesity also increases susceptibility to Acute Respiratory Distress Syndrome (ARDS),
the primary cause of mortality from COVID-19 4.
A Detroit-based study early in the pandemic found obesity to increase overall
mortality by 23%, comparable to hypertension in their study. Additionally, obesity was
correlated with a 17% increased rate of admission to the ICU, and a 37% increase in
3

requiring mechanical ventilation. In comparison, hypertension correlated to a 27% and
29% increased rate respectively 5. Another study from the same found almost half (47.5%)
of patients admitted to the ICU were obese (BMI ≥ 30), and that the distribution was
distinctly different from non–SARS‐CoV‐2 severe acute respiratory syndrome. 6 Further,
68.6% of the ICU patients required mechanical ventilation. The non-COVID-19 patients
were distributed approximately the same as the regional prevalence, with patients with a
BMI > 30 only making up 25.8% of ICU admissions. A study encompassing all COVID19 positive patients under care of the U.S. Veterans Health Administration had findings
consistent with recent studies linking obesity to increased COVID-19 related
hospitalizations, ICU admission, and mortality 7.

2.2 Physiological factors
The association between obesity and adverse outcomes of COVID-19 is likely due
to underlying inflammatory and metabolic factors contributing to decreased lung
volume/expiratory reserve volume, increased inflammatory cytokines and chemokines,
oxidative stress, and development of cardiovascular complications 8. A combination of
physiologic changes (metabolic, immune, and adipose tissue function) associated with

4

comorbidities and physical features (such as obstructive sleep apnea) lead to adverse
clinical manifestations and even impaired vaccine response in persons with obesity.

Figure 1. Presumed Mechanistic Behavior of Infection and Immunity.

For example, in an L.A based study in April of 20209, obese patients were more
than twice as likely to require mechanical ventilation. Elevated levels of Interleukin-6 (IL6), ferritin, lactate dehydrogenase (LDH) and C-reactive protein (CRP) were found in
blood draws from time of admission or day of diagnosis if already admitted and were
associated with increased need for mechanical ventilation or intubation. In a study during
the same period, obese Chinese patients had similarly elevated levels of CRP and
developed more severe symptoms compared to lean patients10.
In addition to physiological factors, SARS-CoV-2 infections and COVID-19
outcomes appear to unsurprisingly carry a strong socioeconomic status (SES) component,
with ethnic minorities bearing the brunt of negative COVID-19 outcomes. Early on, the
discrepancies were noted by professional journals such as the Lancet11, however later
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studies12 have shown disproportionate impact on BIPOC (Black, Indian, People of Color)
communities. When controlling for income levels, one study places mortality for black
patients at rates 215% of white populations, with Hispanic/Latino populations a close 182%
rate.13 Another study places infection incidence rates for black populations at 1.9% for
every 1% of population, and 2.4% for every 1% of Hispanic/Latino population12.

2.3 Sex differences in COVID-19
One factor leading to the greatest disparities in outcomes for COVID-19 positive patients
is biological sex. Early studies from Wuhan noted majority male admittance to ICU and
mortality. A clear correlation between male sex and COVID-19 disease severity and
mortality has since become evident. In a retrospective cohort study of a 3-month period
between April and June of 2020 it was found that among its patients male sex was
independently correlated to a 30% higher mortality risk than females, and risk was
increased with comorbidities as 79%. 14 An analysis of public patient data in China
during the same period placed male mortality rates at approximately 70.3%, 2.4-fold that
of women. Further, 37.2% of male patients suffered symptoms described as critical,
defined by occurrence of respiratory failure that requires mechanical ventilation, shock,
or ICU admission due to combined organ failure.15 A retrospective case study covering
the initial spread of infection in the Lombard Region in Italy found that male patients
required ICU admission at 4-fold the rates of female patients and died at almost twice the
rate of their female counterparts in the ICU 16.
SARS-CoV-1 and Middle East respiratory syndrome coronavirus (MERS-CoV)
had 11% and 34% mortality rates respectively compared to a 4.2-7.3% mortality rate in
COVID-19. Both also had slim majority male mortality, but neither had anywhere near the
6

sex-based variance in mortality or severity despite similar pathologies at play.15,17 The
reason remains unclear, but a combination of physiologic factors likely contributes to sex
differences in various aspects of COVID-19 disease course and severity. For example,
males tend to have more abdominal adipose tissue, responsible for chronic obesity-induced
low-grade inflammation, which is exacerbated by COVID-19-induced inflammatory
responses.18 In addition, the mechanism for SARS-CoV-2 viral entry into cells involves a
more robust (compared to previous viruses) exploitation of a protein called angiotensinconverting enzyme 2 (ACE2) compared to SARS-CoV-1, a multifunctional protein best
known for its counter-regulatory role as part of the renin-angiotensin system (RAS) in the
regulation of blood pressure. As part of the viral mechanism of entry, the normal activity
of the RAS is disrupted. One consequence of this is greatly elevated levels of the peptide
angiotensin II, which can have diverse adverse effects, such as local (lung, kidney, vessel,
heart) inflammation and tissue damage 19. Modulation of the activity of the RAS by sex
hormones contributes to sex differences in development of chronic disease 20 Therefore, it
is theorized that pre-menopausal women with estradiol-mediated effects on the RAS,
affording some protection from hypertension, may translate into reduced severity of
COVID-19

21

. A study of the protective effects of estrogens on male cardiac tissue

identified protein expression profiles with changes in ACE2 and down-regulation of proinflammatory and pro-oxidation effectors like LOX-1 and ICAM-1 22. These data suggest
that discrepancies in COVID-19 mortality between pre-menopausal women and men, that
appears to normalize after around age 45, may be related to various cardioprotective effects
of sex hormones, including their effects on key mediators of the RAS that overlap with the
pathophysiology of COVID-19.

7

2.4 Critical Care Nutrition
Nutritional care for critical care patients is guided by American Society for
Parenteral and Enteral Nutrition (ASPEN) provisions covering a population greater than
18 years of age and a Medica Intensive Care Unit (MICU) or Surgical Intensive Care
Unit (SICU) length of stay greater than 2-3 days23-25, The Guidelines for the Provision
and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient (2016)
covers a broad range of disease states including organ failure (pulmonary, renal, and
liver), acute pancreatitis, surgical subsets (trauma, traumatic brain injury [TBI], open
abdomen [OA], and burns), sepsis, postoperative major surgery. These guidelines apply
to otherwise “normal” adults (healthy weight) in a critical care facility. A different set of
guidelines is required for critically ill patients with obesity as their pathophysiology is
sufficiently different to require different methodologies and care in the critical care
realm. 23 Reasoning for guidelines is multifaceted, mostly based on the provisioning
requirements for differing disease states, treatment regimens, developing risk facts,
secondary factors affecting nutritional or health status (ICU induced weakness, hospital
acquired illnesses, trauma from intubation/mechanical ventilation) or other secondary
etiology24.

2.5 Therapeutic goals:
Nutritional therapeutic goals vary from patient to patient, but there are some
generalizable evidence-based targets suggested by ASPEN and the Society Critical Care
Medicine (SCCM) with the goal of reduced mortality. Of interest in the case of COVID19 patients, previous guidelines had specific recommendations for ARDS 25, while the
most recent suggests simply targeting 12 to 25 kcal/kg and a protein intake of 1.2 to 2.0
g/kg in the first 7-10 days of ICU stay 26. In the context of glycemic control, ASPEN
8

defers to SCCM guidelines of insulin therapy to maintain blood glucose levels in the 140
to 180 mg/dL range as it is not atypical for critical care patients (or often, any long-term
patient subject to hospitalization) to develop hyperglycemia.27

2.6 Nutrition screening.
Dynamic screening for nutritional risk is recommended for critically ill patients.
Screening criteria include parameters in flux rather than static: recent weight loss, current
BMI, change in treatment regimen, expected alterations in nutritional status, etc.
Assessment and subsequent nutritional support objectives should be conducted at the
time of admission to the ICU and during the implementation of enteral nutrition, ideally
within 24-48 hours. Results from a meta-analysis conducted in ICU patients
demonstrated that early enteral nutrition (within 24 h of ICU admission) reduced
mortality compared with delayed enteral intake 28. Tools for nutrition risk screening
include the Nutrition Risk Screening Form (NRS 2002) and use of a a Nutrition Risk in
Critically Ill (NUTRIC) score (or modified NUTRIC score) is recommended for
screening.
Patients may be given a physical exam for assessment of lean muscle mass and
body fat on admittance, but generally those outside of the dietetics field are focused on
injury, signs suggestive of illness (i.e. lesions and HIV, or yellowing eyes and
jaundice/liver dysfunction) and the like. Often, signs of malnutrition must be relatively
extreme for an attending clinician to note. The evaluation of malnutrition should be
repeated regularly and frequently due to the dynamics of the disease and increased risk of
dysphagia in the elderly after pneumonia, and after prolonged respiratory therapy (postextubation dysphagia) 29.

9

2.7 Determination of Estimated Energy Requirements (EER).
Determination of energy requirements for patients, be they minorly injured up to
critically ill patients with obesity, can be a complicated. The gold standard for
determination of energy requirements is indirect calorimetry (IC). IC is highly accurate
and, while preferred, potentially cumbersome to utilize and requires trained personnel to
apply. IC measures O2 consumption and CO2 produced during oxidative phosphorylation
as indirect proxies for heat expenditure and generation during substrate oxidation and
allows accurate estimation within 1% of the metabolic rate of the subject. It also allows
determination of substrate usage for energy production, allowing the healthcare
professionals to glean useful knowledge of the metabolic pathways associated with
energy production. Utilization of IC has over the decades since its introduction led to the
characterization of stress responses to injury and other altered or hypermetabolic states
and subsequent design of appropriate nutrient regimens.
In an

Table 2. Common formulae for determination of caloric needs.

environment where infectious disease concerns reign and exposure is limited, as well as
hygienic concerns over the enclosed devices used to measure outputs, the hood or mask
required for IC is difficult to utilize. Additionally, it does require the patient to be
consume sufficient oxygen without support and intubation or other mechanical
ventilation both physically makes it more difficult to apply IC and alters the input and
outputs sufficiently to make it useless. As such, falling back on standardized formulae to
10

calculate EER based on body weight is the norm in an ICU environment. There are
various formulas for calculation of basal metabolic rate (BMR), summarized in the table
2. Additionally, the BMR is multiplied by an activity modifier, based on level of physical
activity, described in table 3.
These formulae, while fairly accurate in usage on healthy individuals in some BMI
ranges, fail to consider the needs of patients with altered energy intake/expenditure, such
as in obesity. Patients in critical care have altered metabolic needs and patients in critical
care with obesity is even more challenging. Using an expected 25-30 kcal per kg of actual
or ideal body weight may lead to either over- or under-feeding. The H-B formula is
suitable for healthy
individuals but is no
more than 65%
accurate in critically
ill patients and is not
Table 3 Sex based EER ratios in first 5 days

validated for BMI >
30. A somewhat uncommon formula, Ireton-Jones, is suitable for use with patients with
BMI > 30 but is not validated for any patient requiring mechanical ventilation support. 30
The only predictive formula validated for a theoretical patient with obesity in Critical
Care is Penn State University. This is a concern in care of all Critical Care patients, but
not all patients are on Total Parenteral Nutrition (TPN). 31
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According to the 2016 ASPEN/SCCM Guidelines, whenever it is impossible to
measure VCO2 directly, energy requirement needs should be estimated according to body
weight. For non-obese critically ill patients, the recommended amount of energy is 25–30
kcal per day/kg. For
overweight and
obese critically ill
Table 5 Per kilogram estimation of caloric needs in critical care patients

patients, the

recommended amount of energy is 21 kcal per day/kg. In ventilator-dependent obese
patients, the PSU or HBE equations with actual body weight and a stress factor of 1.1 (if
the patient is spontaneously breathing) may be applied. For obese and critically ill
patients, if the BMI is 30–50 kg/m2, the recommended energy target is 11–14 kcal/kg per
day.

2.8 Critical care challenges with obesity and COVID-19.
Due to the high prevalence of obesity in adults, nutrition support clinicians are
encountering greater numbers of obese patients who require nutrition support during
hospitalization. Obesity poses a number of challenges to optimal care in critically ill
patients.
Typically, 20% of critical care patients present with obesity, somewhat less than the
national prevalence 32. Physical challenges include airway positioning and access. Other
challenges include pharmacologic and nutritional support. This has been even more
relevant during the COVID-19 crisis, where the number of ICU patients with obesity
reaches 43.9% (BMI ≥30 and a further 7.3% with severe obesity (BMI ≥40) 32
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Critically ill COVID-19 patients are at risk for malnutrition resulting from imbalances
in energy intake and expenditure which is exacerbated by factors affecting energy
consumption and intake. Critically ill patients can experience dramatic alterations in
energy consumption due to fever, mechanical ventilation, and exacerbated activity of
breathing muscles 33. Reduced or insufficient energy intake can result from reduced
appetite, dyspnea, or intubation, and can further be impaired by adverse effects of SARSCoV-2 on the GI tract 17. Further, existing metabolic disturbances or disorders can have
adverse effects on nutrient metabolism. Challenges to meeting nutritional goals include:
Increased blood sugar and insulin resistance, reduced glucose oxidation, increased
glycolysis and gluconeogenesis; impaired protein metabolism (increased protein
breakdown, and enhanced synthesis of acute phase proteins, decreased muscle protein
synthesis and negative nitrogen balance in the body); and increased fat mobilization.

2.9 Macronutrient considerations
Careful balancing of glucose administration in TPN or of gluconeogenesis via
enteral nutrition (EN) is necessary to balance diet induced thermogenesis (DIT) and
nitrogen loss in catabolism. This is associated with release of insulin and a cascade of
protein-sparing metabolic behaviors that return the body to a level closer to neutral with
regard to protein synthesis and anabolic/catabolic phases. Easily oxidizable substrates
such as glucose and simple amino acid or glutamine-bearing complexes such as ornithine
ketoglutarate added to nutritional intake function as part of a pseudo-sacrificial shield of
preferential metabolism and allow protein synthesis to continue without being interrupted
by catabolic calls for energy from the muscles. This preserves lean body mass associated
with more positive outcomes in patients.
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An additional aspect of critical care regarding standardized formula are
pharmacological effects introduced and with EN or TPN. Lipid infusions as part of TPN
for instance interferes with lung hemodynamics and alters regulation of
ventilation/perfusion ratios in the pulmonary system. Elevation of omega-6 PUFA lipid
supply shifts metabolic balance and oxidative substrate usage towards b-oxidation.
Increased lipid supply also increases synthesis of vasodilating prostaglandins, leading to
increased arachidonic acid that eventually overwhelms the speed of prostaglandin
synthesis and rebounds to drastically increase in thromboxane and leukotrienes which in
turn leads to vasoconstriction. These metabolic alterations lead to worsening gas
exchange, leading to further impairment of ventilatory perfusion. In particular, the
overabundance of thromboxane and leukotrienes reduce PaO2 and increase pulmonary
vascular resistance. This is controllable in many CC instances, but in subjects with sepsis
or ARDS, control is much more difficult and clinically relevant. Further, excess lipid
supply leads to negative effects on immune response and down-regulation or alteration of
the mononuclear phagocyte system, also known as the reticuloendothelial system, that is
a key first line element of immune defense against a range of pathogens. Of import this
includes human respiratory viruses such as hRSV and SARS-CoV-2.8
Broadly, protein intake monitoring should occur in all patients and especially in
critical care patients. Catabolism is common in hospitalized patients in any state and what
may be excessive in a health individual may lead to positive outcomes in many cases
(burns and wound healing being the classic examples.) Supportive and supplementary
protein intake is commonly prescribed for such cases but are again importance in disease
states where lung hemodynamics and perfusion alteration are symptomatic of whatever
14

etiology. Protein administration increases the minute ventilation and respiratory drive
more than would be expected for its increase in Resting Energy Expenditure (REE), and
branch chain amino acids (BCAAs), a common bolus additive for inflammatory states,
further increases the effect. While this may be attenuated by control of PUFA ratios in
EN/TPN in other cases, the increased ventilatory drive can be lethally dangerous in
patients with ARDS or lack the ability to increase their work of breathing. 25,33

2.10 Propofol use in obese critical care patients
Propofol (sold predominately under the brand name Diprivan) is an intravenous
sedative-hypnotic anesthetic agent commonly used for IV induction of maintenance of
general anesthesia, though it is unrelated to other sedative-hypnotic agents. Propofol is
useful in critical care as a sedative-hypnotic agent due to its particular GABA receptor
binding that allows usage with intravenous pain relief drugs (commonly fentanyl) without
additional respiratory depression. Propofol can produce hypercapnia in patients, the
persistence of which can depend on volume dosing and rate of administration. This
potentially leads to decreases in respiratory rate, minute volume, tidal volume, and
functional residual capacity It has a rapid onset, provides rapid recovery after bolus or
infusion removal, and has anti-emetic properties. Its highly lipophilic nature allows it to
cross the blood-brain barrier leading to said rapid onset. Emergence is also quick, as the
drug is redistributed to peripheral tissue and tissues and follow-up metabolic clearance.
These characteristics make propofol a common intravenously delivered induction agent
in hospitals or ambulatory clinics where it is used as a part of almost every modern Total
Intravenous Anesthesia. As a sedative, propofol is preferably delivered on a per kilogram
basis using either adjusted body weight or Ideal body Weight (IBW) to avoid
supratherapeutic concentrations in cases where patients are excessively outside the
15

accepted normal range for their height when using actual body weight. This is important
to consider because body weight and drug clearance are not linearly correlated.
Due to the lipophilic qualities, propofol administration requires a carrier vehicle
of (soybean) oil and (egg) lecithin as a white, stable emulsion for intravenous delivery.
Most lipids (and other absorbed nutrients or materials) are delivered to the liver via the
hepatic portal vein after enrichment along the tissues of the GI tract. Intravenous
administration of this drug and its vehicle maintains a caloric content equivalent to lipids
consumed (e.g. 9 kcal/g). As propofol is delivered as an emulsion, it is commonly
calculated at 1.1 kcal/mL and 10mg of propofol itself per mL of solution is administered.
Dosing recommendations can be somewhat confusing, as both mg/kg/hr and mL/kg/hr
are commonly used, sometimes interchangeably, in recommendation guidelines. For
patients with obesity, calculations purely focused on weight have multiple issues or
concerns. Linear scaling by weight does not take into account issues previously discussed
such as the lipophilic nature of the drug causing alteration of pharmacokinetics and
therapeutic dosing, as well as altering times for onset and recovery of sedation.
Critically ill patients receive a much larger percentage of their daily energy intake
as lipid (<55%) compared to the recommended >35% daily intake for healthy adults
aiming to reduce their risk of cardiovascular disease. Some studies indicate that highdoses of long-chain triacylglycerols in critically ill patients lead to poorer outcomes34.
This becomes concerning in obese patients who may be consuming far greater lipid
content as energy from propofol delivery than from dietary sources. Given the metabolic
alterations in lipid metabolism during critical illness (where hypertriglyceridemia is
observed in a large percentage (45%) of patients requiring multiple days of ICU care), the
16

contribution of propofol (i.e excess lipids) to energy intake in obese persons could have a
negative impact on outcomes. An additional factor is the potential replacement of
carbohydrate and protein macronutrients to accommodate the addition calories from
propofol delivery.
In a retrospective analysis, the quantity of lipid and the proportion of both energy
and lipids in propofol-sedated critically ill adults was determined in two ICU centers (n =
701) for a total of 3,484 propofol days.35 The energy targets were approximately 1,987
kcal/day, and mean energy intake was approximately 70% of targets. The mean propofol
sedation dose was 2,045 + 1,650 mg/day an (additional 146 kcal/per day). Fat constituted
17% of total energy. Fat delivery was significantly increased in propofol-sedated patients
receiving high-fat formula EN feeds. In survivors, high-fat proportion was associated
with prolonged ventilation time. These data indicate that fat content with propofol
delivery is greatly increased in critical care. Further, the authors noted that in the early
days of ICU stay, fat content from propofol could constitute up to 100% of energy intake
in some patients. This study did not determine additional effects in obese patients.
In a study published in the Journal of Parenteral and Enteral Nutrition, medical
records from n = 370 patients were retrospectively analyzed for proportion of total daily
energy provided as propofol, overall energy balance, hospital mortality, duration of
mechanical ventilation and ICU LOS. Patients administered propofol received a greater
proportion of their total energy prescription compared with those who were not.
Proportion of energy provided as propofol was not significantly associated with
outcomes. The authors demonstrated that the proportion of propofol and associated lipid
calorie content were greatest in the early days of ICU care (i.e. day 1 and 2), but that 53%
17

of patients were receiving 80% of EER on day 3. Overfeeding was observed in
approximately 1 in 5 patients receiving propofol on day 5. Overall, protein delivery was
poor (<1.2 g/kg/day). These data suggest that obese persons receiving propofol during
ICU stay may be at risk for either over-feeding or replacement of protein (shown in
separate studies to be positively associated with critical care outcomes) with lipid as
vehicle for propofol delivery.
Data regarding critical care nutrition and metabolism in patients with COVID-19
is scarce, given the novelty of this disease. Much research has been focused on drug
treatments or management of respiratory conditions. Because patients with COVID-19
often require prolonged mechanical ventilation, they might receive large quantities of
propofol, which could be of particular concern to the large numbers of patients with
COVID-19 who are obese. In a recent prospective observational study, it was reported
during the first 10 days, COVID‐19 patients received more lipid (propofol sedation) and
less protein compared to patients with persistent critical illness, without COVID-19 and
prescribed energy targets were below those of the ICU protocol 36.

2.11 Sex differences in critical illness:
2.11.1 Gaps in literature
We have examined factors contributing to outcomes in critically ill patients with
COVID-19. Outcomes in COVID-19 are significantly impacted by male sex and presence
of comorbidities (especially those related to cardiometabolic risk). Sex differences in
critical care demonstrate that females compared to males, may receive less appropriate
care for management of ARDS. However, female sex hormones may have protective
effects in critical illness states. COVID-19 patients with obesity may have increased
challenges with nutrition in a critical care setting, due to the increased delivery of highly
18

lipophilic propofol with prolonged mechanical ventilation. However, the impact of the
quality of nutrition care, and whether there are sex differences in critical care nutrition
with COVID-19 contributing to the increased severity of disease in men versus women
are unknown.
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3. Methodology
3.1 Aggregate data from i2b2.
At the time the data were collected, February 2021, sex differences in COVID-19
diagnosis and outcomes were emergent. To determine whether global trends
demonstrating increased severity and outcomes of COVID-19 infection were present in
the population served by the University of Kentucky, we collected aggregate data from
UKHealthcare. We used the i2b2 patient survey portal to
query the following terms: COVID (Diagnostic Code) and
with or without Hypertensive Diseases (Diagnostic Code =
I10 – I15). We examined the incidence of COVID-19
diagnosis in adults across each BMI category, with or
without a diagnosis of hypertensive disorders, and grouped
by sex (men or women) – See Figure 2 for an example
search.
To further confirm global
Figure 2 i2b2 portal query

trends of male sex being associated with
increased ICU admissions over the course of the pandemic, we
again queried i2b2 using the terms for confirmed COVID-19
diagnosis and Acute Respiratory Distress (see figure 3).

Figure 3 i2b2 portal query with
COVID diagnosis
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3.2 Clinical cohort.
To determine whether there were sex differences in critical care nutrition, we
retrospectively examined a cohort of n=31 men and women admitted to the Medical
Intensive Care Unit at UK Chandler Hospital between March 2020 – February 2021. This
cohort consisted of men and women who received critical care for acute COVID-19 and
were subsequently followed in the post-ICU clinic (PICS) at UK. The patients were
originally selected as part of a pilot study to examine pulmonary outcomes in the PICS
clinic. Collection of acute data for this study was approved under the University-wide
IRB approved COVID-19 Registry and Specimen Biobank. Pertinent clinical data were
abstracted from electronic medical records (EMR) via Sunrise Clinical Manager (SCM)
and stored in a secure, IRB-approved REDCap database. Data from the pilot cohort, used
for clinical nutrition investigation in the current study were obtained via collaboration
with Dr. Sturgill, and included demographic variables of: age, sex, race, smoking status,
weight and height used for the calculation of BMI; risk factors related to lung outcomes
of: chronic and interstitial lung disease, asthma, COPD, pulmonary hypertension, and
obstructive sleep apnea. Variables for hospital disease course included: Charleston index
and SOFA score (indices of disease severity), length of hospital and ICU stay, and length
of mechanical ventilation.
Eligibility criteria for patients admitted for critical care include one or more of the
following in patients who were previously admitted to the ICU: > 48 hours of mechanical
ventilation, new tracheostomy, > 72 hours septic shock requiring vasopressor, new multiorgan system failure (at least 2 organ systems), ICU-acquired weakness (<48/60 on
medical research council-sumscore), delirium or acute respiratory syndrome diagnosed in
the ICU, > 48 hours required extracorporeal membrane oxygenation.
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3.3 Clinical nutrition data collection.
We collected clinical nutrition data from medical records of n=31 men and women
admitted to critical care with COVID-19 who received propofol (for mechanical
ventilation) concurrent with enteral nutrition during their ICU stay. Of the n=31 patients
whose received enteral nutrition during the acute ICU stay, there were wide variations in
the number of enteral nutrition and/or propofol days. Therefore, a 14-day period
beginning with admittance or transfer to COVID-19 ICU ward was selected.
For each patient, data was extracted from dietitian Assessment, Diagnosis,
Intervention, Monitoring/Evaluation (ADIME) notes recorded in SCM at each time of
nutrition care assessment. Values for energy recommendations, daily energy intake (as
mL of formula delivered), and propofol (as mL delivered in a lipid infusion) were used to
calculate energy intake as kcal (including macronutrient breakdown) as well as energy
derived from propofol as a lipid infusion.
Energy recommendations from dietitian notes were reported as kcal per kilogram
per day, and concurrently reported body mass was used for the calculation of total daily
kcal requirements. UKHC utilizes five different EN formulas, and mL/hr bolus from
notes was used to determine mL delivered per formula. Daily energy (in kcal) and
macronutrient intakes (in grams of protein, carbohydrate, and lipid) were calculated from
the volume of formula delivered. This volume was converted into total energy intake by
multiplying the volume of formula delivered by the energy content in kcal per mL for
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each type of formula used, Table. Daily
macronutrient intakes in kcal from formula
were similarly calculated on a g/mL basis
based on individual formula concentrations.
Table 6 Formulary calorie values by type.

The amount of propofol each patient received per day was a volume in mL was
abstracted from SCM and energy received from propofol, as well as energy from lipids
received as part of the propofol delivery, were calculated from the following formulae:
Energy received from propofol (Kcal): energy received from propofol as mL propofol
received × 1.1kcal/mL (content reported from the manufacture)
Lipid received from propofol (g): lipids received from propofol as mL propofol received
× 0.1222 = total grams lipid from propofol .
As with energy intake and macronutrient values, these values were calculated on a perday basis, and also averaged over a 14-day period.
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4. Results
4.1 Sex differences in COVID-19 diagnosis with or without hypertension.
Aggregate data from UKHealthcare i2b2 patient survey portal was retrieved in
February 2021 using the query terms: COVID and with or without Hypertensive Diseases
across each BMI category and grouped by sex (men or women). Of the 3437 patients
with a SARS-CoV-2 diagnosis, 2091 (60.8%) were women and 1346 (39.2%) were men.
Across each BMI category, there were more women compared to men with a SARSCoV-2 diagnosis. Of the 2971 patients with a SARS-CoV-2 diagnosis and a concomitant
diagnosis of hypertensive diseases, 1499 (50.5%) were women and 1472 (49.5%) were
men. In patients who also had hypertension, there were more men than women with a
SARS-CoV-2 diagnosis in the normal and overweight BMI categories. However, in the
obese categories, there were more women than men with SARS-CoV-2 diagnosis and
hypertension. These data suggest sex differences in SARS-CoV-2 prevalence are
influenced by obesity and hypertension.
Data retrieved from July 2022 using the query terms for confirmed SARS-CoV-2
diagnosis and Acute Respiratory Distress indicate approx. 2120 adults over the age of 18
admitted to UKHealthcare, about 984 (46%) women and 1139 (54%) men. These data
indicate more men than women were admitted to critical care with COVID-19 caused by
SARS-CoV-2, consistent with literature that men have worse outcomes than women.

4.2 Propofol and critical nutrition care.
Patient characteristics and nutritional info are described in Table B. There were 15 men
and 16 women in our cohort. The mean BMI was 35.3 and 35.9 kg/m2 respectively, with
no difference between men and women. Similarly, there was no difference in the hospital
or ICU length of stay. Energy intake was the lowest in the first 5 days of ICU stay.
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Figure 4 demonstrates that EER is the lowest in the first day of ICU stay and increases
each day. Although it varied on some days between men
and women, there were no significant differences in EER
among men and women.
There were no significant
differences in the nutritional
parameters. Men and women
Figure 4 Sex based EER ratios in first
5 days

received similar daily kcal during

the 14-day period (998 versus 950 kcal/day), which represented
51.7% and 57.9% EER, respectively. In this period, propofol

Figure 5 Sex based propofol intake in
first 5 days

consisted of 21% of total kcal delivered in men and 17.1% of total kcal delivered in
women. Men and women received approximately 46 grams of lipid on days with propofol
delivery, which was comprised of 21% of lipid intake of propofol in men and 17.6 % of
lipid intake of propofol in women.
However, the macronutritional profile varied slightly between men and women. In the
same 14-day period, men received 51.8% of total kcals from total lipids derived from
propofol and formula, while women received 56.4% of their total kcals from total lipids.
While not significant, the sex-based variation of total proportion of protein and
carbohydrates delivered was striking. After controlling for
body mass, Men received approximately 60.3 grams of
protein daily (17.8% of total kcal intake) while women
received 65.9 grams of protein (21.5% of total kcal intake.)
Figure 6 Sex based formula intake in
first 5 days
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Men received 93 grams of carbohydrate daily (28.1% total kcal) but women received
63.3 grams daily (equating to 19.4% of total kcal.)
Parameter

Male
N = 15

Female
N = 16

HOSP LOS

30.1 ± 7.2

27.3 ± 10.0

ICU LOS

15.8 ±

14.1 ± 6.9

BMI

37.5 ± 7.0

37.3 ± 9.3

Kcal (daily)

1048 ± 229

973 ± 188.9

% EER received

51.7% ± 18.0

56.4% ± 17.6

P.D

6.5 ± 3.8

6.6 ± 4.3

Avg lipid intake propofol,

46.4 ± 27.5

48.7 ± 22.0

21.1% ± 16.1

22.1% ± 14.5

formula Lipid % kcal

38.5% ± 4.3

36.7% ± 3.7

Total % diet lipid

51.8%

56.4%

Fed. Avg. PROT (g)

60.3 ± 23.4

64.2 ± 30.9

PROT diet %

23.9% ± 9.3

27.0% ± 12.2

Fed. Avg. CHO (g)

93.0 ± 24.9

80.3 ± 16.6

CHO diet %

35.2% ± 4.3

33.1% ± 4.3

g
Avg lipid intake propofol,
% of kcal

Table 7 Cohort characteristics
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5. Discussion
This study examined sex differences in SARS-CoV-2 diagnosis, admittance into critical
care, and in critical care nutrition therapy. Using aggregate data from UKHealthcare, we
found that between the period April 1, 2020 – February 23, 2021 , there were more
women than men with a COVID-19 diagnosis. However, when including hypertension as
a comorbidity, more men than women were diagnosed with COVID-19. Further,
aggregate data revealed that more men than women were admitted into critical care with
COVID-19 for the period described. We examined whether sex differences in critical
care nutritional therapy could be a factor contributing to the known increased severity of
COVID-19 in men. While there were generally no differences in nutritional parameters in
our cohort, we observed a trend of elevated protein intake in women versus men. This
was associated with proportionally less propofol intake in women. This suggests that in
our cohort, women were able to receive more kcal as nutrition (and specifically protein)
than lipid in the form of propofol compared to men. Since both the overall kcal intake
and protein intake during critical care are associated with outcomes, our data (while not
significant), suggest that better nutrition during acute critical care for COVID might
contribute to the better (acute) outcomes in women compared to men.
Since the global outbreak of SARS-CoV-2, numerous data indicate there are
significant sex differences in COVID-19 severity and outcomes. Specifically, the number
of critical care admissions is greatly increased in men 37,38. In the current study, we used
aggregate data from UKHealthcare to determine whether trends in our region were
similar to global trends. We found that a COVID-19 diagnosis in patients with
hypertension was more prevalent in men versus women. This is supported by literature
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that the presence of comorbidities greatly increases the severity of COVID-19 disease
course in men versus women 16. Our data also indicated that more men than women were
admitted into critical care at UK, which is also in agreement with both national and
global trends. 1
Many factors, including physiological, biological, sociocultural, etc, contribute to
sex differences in COVID disease severity. These include, for example, the number of
ACE2 receptors available for virus binding22, hormonal factors that may be protective
(e.g. estrogen) 39, gender discrepancies in self-care/behavior 13,38. We wanted to examine
the impact of nutrition therapy during critical care. Reasons for this include the wellknown associations among critical care nutrition and ICU outcomes 27,40, and because
patients with COVID-19 require sustained mechanical ventilation and are given very
large amounts of propofol (in a highly calorific lipid emulsion vehicle) beyond the
historical uses of this agent. Further, there is a dearth of evidence of sex differences in
critical care nutrition therapy (especially with respect to propofol usage). We found
amount of propofol used was limited to generally 3 to 5 day (post-surgical) up to a limit
of 5 to 10 days in ICU sedation cases. 41

5.1 Limitations
The limitations of the study I performed for this analysis were somewhat clear at the start
time, given the cohort used. Some of the more pertinent issues lay with the data set
focusing on COVID-19 patients who 1) were admitted to the ICU 2) survived their
infection, 3) consented to the cardiopulmonary study that the data was extracted from, 4)
attended the clinic and 5) attended follow-up. This restricts some more obvious
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outcomes (e.g. mortality rates) and excludes a number of individuals (the initial cohort
was greater than 240, but was cut down once eligibility criteria were applied.

5.2 Future Directions
An obvious direction to this research would be to recruit a broader cohort without
some of the defining subject limitations from the study we sourced our own cohort. This
cohort was narrowly defined and excluded a number of subjects that may have impacted
our findings (e.g. mortality or extremely poor outcome patients that were incapable of
attending the cardiopulmonary clinic) in one direction or another. While we may have
seen the “healthier” extreme of the UKHC patients, the less healthy extreme would be
where we could potentially identify negative impacts of propofol and lipid intake.
Additionally, a larger cohort would improve the statistical power and potentially improve
any significance that is teetering on the grey area of 0.5 to 0.10.
Additional research that may be of interest to this topic of nutritional status
impact on ICU patients is difficult draw back to a wet bench or animal study level. Longterm propofol usage or mechanical ventilation in lab animals is not common, and
COVID-19 mouse models are not especially similar physiologically. Inflammatory
reactions, mACE2 entry vectors, hormonal impacts, and RAAS alterations have
similarities, but appear to be significantly different from humans in some mouse models42
with neurological impact similarities approaching zero43. Longitudinal studies of patients
as COVID-19 remains a common viral infection may remain the best plan, with
identification of several potential key markers of interest (cytokine markers, lipid panels,
etc.) ahead of time and a testing methodology settled before recruitment and patients
tracked during their stay rather than long after. Additionally, with a cohort “currently”
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admitted, potential errors in I/O and weight tracking could be dealt with as needed and
any issues cropping up (e.g., patient inability to handle formula secondary to disease vs
alternative reasons) clarified for analyses.
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6. Conclusion
Our data shows that the population treated at UK Chandler hospital broadly
follows the global trends at the time of collection, with an excess of male patients
admitted both to the hospital and ICU and apparent severity (via SOFA score) divided as
well. There are clear sex based differences seen in at least the earlier strains of COVID19. The presumed connection between lipid intake via propofol, limited macronutrient
intake, and mechanical ventilation or length of stay was not apparent in the cohort
analyzed. Further analysis with an expanded cohort with less stringent inclusion criteria
may find some connections that are not clear in these analyses.
While this study may have been unable to identify a connection between COVID19 patient outcomes and propofol intake, potentially due to limitations with the cohort,
COVID-19 continues to both affect people worldwide. Given there are several variant
diseases in this family that previously affected global populations to a lesser extent and
the potential for further coronavirus outbreaks or mutations, we strongly recommended
further research in the topic if propofol and mechanical ventilation requirements continue
to be extensive in such a large population.
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Definitions & Formulae
Propofol delivery:
Propofol (mL) is defined as amount in a given 24-hr period was determined by [adding
up?] propofol IV indication in I/O portion of patient records and compared to ordered
amount in doctors notes.
Propofol Days (P.D) are defined as 24-hr periods where patients received ≥ 100 mL of
1% propofol, equivalent to 1000 mg of active drug.
Total Propofol Intake (TPI) is defined as total received propofol solution in the described
14-day period.
Propofol day averages is defined as TPI ÷ P.D.

Nutrition Delivery:
Formula (mL) is defined as total enteral nutrition delivered in a given 24-hr period as
determined from I/O portion of patient records and compared to recommendation in
Dietitian ADIME notes
Fed Days (F.D.) are defined as 24-hr periods where patients received ≥ trophic feeding
levels (10-20mL/hr) during administration. Cut-off determined by I/O records, not
Formula (mL) ÷ 24-hrs.
Total VHP/Total DBS/Total Renal/Total Replete/Total Isosource
Total VHP: Total mL Peptamen Very High Protein formula
Total DBS: Total mL Diabetisource AC formula
Total Renal: Total mL Novasource Renal formula
Total Replete: Total mL Replete Liquid formula
Total Isosource: Total mL IsoSource 1.5 formula
Total formula intake (mL) (TFI): is defined as total received enteral nutrition given in the
described 14-day period
Total Daily Avg (ml): Is defined as total formula intake ÷ 14 days
Fed day Avg (ml): is defined as total formula intake ÷ Fed Days
EER (kcal/day): “Estimated energy requirements” as defined by dietitian in ADIME
notes
EER Total (kcal over stay) Total energy intake recommendation over the described 14day period
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EER avg (kcal/day): EER Total ÷ 14 days
Protein recommendation (g/day): grams of protein recommended as defined by Dietitian
in ADIME notes
Protein recommendation avg (g/day): Total grams of protein recommended ÷ 14-days
Energy received from formula (Kcal): is defined as total kcals derived from enteral
nutrition
Total: Sum of VHP + DBS + Renal + Replete + Isosource =
Average: Total energy received from formula ÷ 14-day period
F.D. Average: Total energy received from formula ÷ Fed Days
VHP: [Total mL VHP × 1 kcal/mL] = Total kcal from VHP
DBS: [Total mL DBS × 1.2 kcals/mL] = Total kcal from TBS
Renal: [Total mL Renal × 2 kcal/mL] = Total kcal from Renal
Replete: [Total mL Replete × 1 kcal/mL] = Total kcal from Replete
Isosource: [Total mL Isosource 1.5 × 1.5 kcal/mL] = Total kcal from Isosource
Lipid received from formula (g)
Total: Sum of VHP + DBS + Renal + Replete + Isosource = Total
Average: Total lipid received from formula ÷ 14-day period
F.D. Average: Total lipid received from formula ÷ Fed Days
VHP: [Total mL VHP × 0.038 g/mL] = Total grams lipid from VHP
DBS: [Total mL DBS × 0.059 g/mL] = Total grams lipid from TBS
Renal: [Total mL Renal × 0.1005g/mL] = Total grams lipid from Renal
Replete: [Total mL Replete × 0.034 g/mL] = Total grams lipid from Replete
Isosource: [Total mL Isosource 1.5 × 0.059g/mL] = Total grams lipid from
Isosource

Energy received from propofol (Kcal): energy received from propofol as mL propofol
received × 1.1kcal/mL
Lipid received from propofol (g): lipids received from propofol as mL propofol received
× 0.1222 = total grams lipid from propofol
CHO received from formula (g)
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Total: Sum of VHP + DBS + Renal + Replete + Isosource = Total grams
carbohydrate received
Average: Total grams carbohydrate received ÷ 14-day period
F.D. Average: Total grams carbohydrate received ÷ Fed Days
VHP: [Total mL VHP × 0.076 g/mL] = Total grams carbohydrate from VHP
DBS: [Total mL DBS × 0.1 g/mL] = Total grams carbohydrate from TBS
Renal: [Total mL Renal × 0.184 g/mL] = Total grams carbohydrate from Renal
Replete: [Total mL Replete × 0.112 g/mL] = Total grams carbohydrate from
Replete
Isosource: [Total mL Isosource 1.5 × 0.176 g/mL] = Total grams carbohydrate
from Isosource
PROT received from formula (g)
Total: Sum of VHP + DBS + Renal + Replete + Isosource = Total grams protein
received
Average: Total grams protein received ÷ 14-day period
F.D. Average: Total grams protein received ÷ Fed Days
VHP: [Total mL VHP × 0.092 g/mL] = Total grams protein from VHP
DBS: [Total mL DBS × 0.015 g/mL] = Total grams protein from TBS
Renal: [Total mL Renal × 0.091 /mL] = Total grams protein from Renal
Replete: [Total mL Replete × 0.064 g/mL] = Total grams protein from Replete
Isosource: [Total mL Isosource 1.5 × 0.068 g/mL] = Total grams protein from
Isosource
Total energy intake (kcal): [Total energy received from formula + Total energy from
propofol = total energy intake in kcals]
Overall avg energy intake (kcal): Total Energy Intake ÷ 14-days
Total lipid intake (kcal): Total lipid received from propofol (g) + Total lipid received
from formula (g)
Total % formula (kcal): Total Energy received from formula ÷ total energy intake =
proportion of total energy from enteral formula
Total % propofol (kcal): Total energy received from propofol ÷ total energy intake =
proportion of total energy from propofol
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Total % lipid (in kcal): [Total Lipid received from propofol (g) + Total lipid received
formula (g)] × 9 kcal/g lipid ÷ Total Energy intake = Total proportion of energy from
lipids
Avg % lipid (in kcal):
Total CHO intake (kcal): [Total grams carbohydrate received from formula × 4kcal/g] =
Total kcals received from carbohydrates
Total % CHO (in kcal): Total kcals received from carbohydrates ÷ Total Energy Intake =
Proportion of kcal from carbohydrates
Avg % CHO (in kcal): Total CHO kcals ÷ 14-day period
Total PROT intake (kcal): Total protein x 4
Total % PROT (in kcal): Total PROT intake ÷ Total Kcal
Avg % PROT (kcal): Total PROT ÷ 14-day period
Total intake/Total EER ratio: Total Kcal intake ÷ Total EER value
Total Lipid % of kcal: Total Lipid Intake ÷ Total Kcals
EN/IV Nutrient day count: Specifies days when non-propofol NPO nutrition was
delivered to patient
Average lipid %: Total Lipid Intake ÷ 14-day period
Propofol Lipid % of kcal: Total lipids (g) from Propofol x 9 ÷ Total kcal received
Formula Lipid % of kcal: Total lipids (g) from formula x 9 ÷ Total kcal received
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